Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy (Q82976088)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

18 January 2020

main subject

1 reference

inferred from title

phase II clinical trial

1 reference

1 reference

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Ken Wyman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Michael B Atkins

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Victor Prieto

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

David F McDermott

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Francie Hubbard

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Christine Byrnes

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Kathleen Sanders

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jeffrey A Sosman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 May 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

2005-2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Lack of clinical efficacy of imatinib in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21834

7 January 2021

Identifiers

DOI

10.1002/CNCR.21834

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565971%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference